Alexander S. Pym

5 ta ish

Africa Health Research Institute

1. Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

   Andreas H. Diacon, Alexander S. Pym, Martin P. Grobusch +13

   MaqolaOAOchiq kirish20144 iqtibos

   ABIABI:AkademIndex/2026.other.034203

2. Randomized Pilot Trial of Eight Weeks of Bedaquiline (TMC207) Treatment for Multidrug-Resistant Tuberculosis: Long-Term Outcome, Tolerability, and Effect on Emergence of Drug Resistance

   Andreas H. Diacon, Peter R. Donald, Alexander S. Pym +11

   MaqolaOAOchiq kirish20123 iqtibos

   ABIABI:AkademIndex/2026.other.185768

3. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis

   Alexander S. Pym, Andreas H. Diacon, Shenjie Tang +13

   MaqolaOAOchiq kirish20152 iqtibos

   ABIABI:AkademIndex/2026.other.034200

4. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis

   Rodney Dawson, Andreas H. Diacon, Daniel E. Everitt +16

   Maqola20152 iqtibos

   ABIABI:AkademIndex/2026.other.364686

5. Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients

   Camus Nimmo, James Millard, Kayleen Brien +9

   Boshqa20202 iqtibos

   ABIABI:AkademIndex/2026.other.373647